SEARCH

SEARCH BY CITATION

References

  • 1
    Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003; 362; 305315.
  • 2
    Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J. Clin. 2003; 53; 526.
  • 3
    Xu YH, Richert N, Ito S, Merlino GT, Pastan I. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc. Natl Acad. Sci. USA 1984; 81; 73087312.
  • 4
    Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366; 216.
  • 5
    Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 2003; 21; 37983807.
  • 6
    Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst. 2005; 97; 643655.
  • 7
    Shia J, Klimstra DS, Li AR et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod. Pathol. 2005; 18; 13501356.
  • 8
    Wang X, Zhang S, MacLennan GT et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin. Cancer Res. 2007; 13; 953957.
  • 9
    Perez EA. The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies. Curr. Oncol. Rep. 2001; 3; 516522.
  • 10
    Ishitoya J, Toriyama M, Oguchi N et al. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Br. J. Cancer 1989; 59; 559562.
  • 11
    Wang KL, Wu TT, Choi IS et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007; 109; 658667.
  • 12
    Lemoine NR, Jain S, Silvestre F et al. Amplification and overexpression of the EGF receptor and c-erbB-2 protooncogenes in human stomach cancer. Br. J. Cancer 1991; 64; 7983.
  • 13
    Kimura M, Tsuda H, Morita D et al. Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. Jpn. J. Clin. Oncol. 2005; 35; 324331.
  • 14
    Kimura M, Tsuda H, Morita D et al. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch. 2004; 445; 255262.
  • 15
    Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer. Cancer 1993; 71; 24542460.
  • 16
    Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 2002; 20; 1S13S.
  • 17
    Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N. Engl. J. Med. 2004; 351; 337345.
  • 18
    Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004; 22; 12011208.
  • 19
    Amann J, Kalyankrishna S, Massion PP et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005; 65; 226235.
  • 20
    Rojo F, Tabernero J, Albanell J et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J. Clin. Oncol. 2006; 24; 43094316.
  • 21
    Bhargava R, Chen B, Klimstra DS et al. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas and normal mucosa. Cancer 2006; 106; 18571862.
  • 22
    Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann. Oncol. 2001; 12; S81S87.
  • 23
    Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 2005; 23; 24452459.
  • 24
    Tripp SR, Willmore-Payne C, Layfield LJ. Relationship between EGFR overexpression and gene amplification status in central nervous system gliomas. Anal. Quant. Cytol. Histol. 2005; 27; 7178.
  • 25
    Mammano E, Belluco C, Sciro M et al. Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer. Anticancer Res. 2006; 26; 35473550.
  • 26
    Mimori K, Nagahara H, Sudo T et al. The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers. J. Surg. Oncol. 2006; 93; 4446.
  • 27
    Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005; 23; 18031810.
  • 28
    Dragovich T, McCoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. 2006; 24; 49224927.